Using an IUD could significantly lower your ovarian cancer risk
From hormonal options to natural family planning, finding the right birth control method is a deeply personal decision—but luckily, you have choices. Understanding the risks and benefits of each option can help you make an informed choice that aligns with your body and lifestyle. Intrauterine devices (IUDs) are a popular choice for women who don’t want to remember to take a pill every day or are looking for a low-maintenance form of birth control. Some women love that the hormonal IUD shortens or even stops menstruation altogether. According to the American Cancer Society, nearly 20,000 women in the US will be diagnosed with ovarian cancer in 2023. “Ovarian cancer continues to be such a challenging cancer because the great majority of these cancers are still diagnosed in late stages,” shares Elena Ratner, MD, gynecologic oncologist at Yale Cancer Center.Source: Motherly
Dr. Alessandro Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, co-chief, Section of Gynecologic Oncology, Yale Cancer Center, discusses the investigation of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial carcinoma overexpressing TROP2. Investigators launched a 2-stage phase 2 clinical trial (NCT04251416) to evaluate the use of sacituzumab govitecan in this patient population. The preliminary responses from this study were presented at the 2023 ASCO Annual Meeting.Source: OncLive
Women With Endometriosis Also Genetically Predisposed to Depression, Anxiety, and Eating Disorders
The largest epidemiological study to date on the psychiatric factors that can accompany endometriosis has demonstrated that depression, anxiety, and eating disorders are not only a result of the chronic pain endometriosis generates, but also have their own underlying genetic mechanisms.
Women’s Health 2023: What We Know and Why it Matters
The work of Women's Health Research at Yale was featured during a March event at the Yale Club of New York City. The event focused on the importance of studying issues related to the health of women and the influence sex and gender have on health.
Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer
Alessandro Santin, MD, professor, Obstetrics, Gynecology, and Reproductive Sciences, Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center, co-chief, Section of Gynecologic Oncology, discusses the clinical activity of sacituzumab govitecan-hziy (Trodelvy) in patients with recurrent endometrial cancer who overexpress Trop-2. Preliminary results from stage 1 of a phase 2 trial (NCT04251416) presented at the 2023 ASCO Annual Meeting showed that among 21 patients evaluable for efficacy, the objective response rate was 33.3%, including 1 (4.8%) complete response and 6 (28.5%) partial responses. Additionally, 47.6% of patients had stable disease, and 14.3% experienced progressive disease. Notably, in 20 patients evaluable for disease control, the 6-month durable disease control rate was 35.0%.Source: OncLive
What Black Women With Ovarian Cancer Need to Know About Genetic Testing
If you are a Black American who’s already living with ovarian cancer, genetic testing may not be top of mind. But medical guidelines state that anyone diagnosed with ovarian, fallopian tube, or primary peritoneal cancer should be offered genetic testing, because it can help you make informed decisions about your cancer journey. Having genetic testing after an ovarian cancer diagnosis could actually mean saving your life, as well as the lives of both the women and men in your family. But, because Black Americans with ovarian cancer are far less likely than white Americans to get genetic testing, it’s important to have all the information and resources available to make sure everyone who needs testing has access to it. “If you don’t know your underlying genetic test results, you can’t be offered life-preserving or lifesaving therapy,” says Elena Ratner, MD, a gynecologic oncologist at Yale Cancer Center in New Haven, Connecticut.Source: Everyday Health
New Data Reported From Trials of Drug Developed at Yale Pathology to Treat Rare, Often Fatal Neonatal Disorder
Clinical trial data from an enzyme-therapy drug developed at Yale Pathology to treat a rare and often fatal neonatal calcification disorder were recently reported. The drug, INZ-701, was designed and validated in the laboratory of Demetrios Braddock, MD, PhD, Associate Professor of Pathology at Yale School of Medicine.
Ideal gestational weight gain varies by pre-pregnancy BMI in twin pregnancy
For people giving birth to twins, the gestational weight gain range with the lowest risk for adverse perinatal outcomes was similar among those with a pre-pregnancy BMI of underweight or normal weight. However, the ideal range for gestational weight gain (GWG) for twin pregnancy decreased with each successively higher BMI category, data in JAMA Network Open showed. The data suggest that the current United States Institute of Medicine GWG recommendations should be lower.Source: Healio
Rare medical book collection tracks tangled history of women’s health
The history of women's health is captured in a new display of antique books at Second Story Books in D.C. The rare volumes — all on view, for sale and available to handle — track centuries of evolving knowledge in the fields of gynecology, obstetrics and more.Source: The Washington Post